We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The earnings call presented several strategic initiatives aimed at improving ENDRA's focus and operational efficiency, alongside positive developments in management, regulatory strategy, and intellectual property. However, financial challenges and stock performance issues remain concerns.
During the ENDRA Life Sciences Q2 2024 earnings call, significant guidance was provided by the management team, outlining various strategic initiatives. Notably, the company has completed a 1-for-50 reverse stock split aimed at maintaining its NASDAQ listing, though recent high warrant exercise volumes have impacted their stock price adversely. Six key operational changes were introduced, including the enhancement of the management team with the addition of a seasoned CFO and a new Head of Clinical and Regulatory Affairs. The company plans to conduct a statistically-powered multicenter prospective clinical trial, expanding the number of subjects from 20 to 250. The financial update revealed a $7.3 million net raise from a public offering, with operating expenses reduced by 26% on an annual basis. ENDRA's goal is to complete clinical work and submit a de novo application to the FDA by mid-2025, with the current cash runway projected to fund the company into the first half of 2025. The management reiterated their confidence in ENDRA's technology and market potential, highlighting ongoing efforts to formalize a long-term business strategy and improve financial execution.
ENDRA has strengthened its management team by adding two experienced operators: Richard Jacroux as CFO and Ziad Rouag as Head of Clinical and Regulatory Affairs, both bringing significant expertise in transforming technology companies and navigating regulatory processes.
The company is implementing a new FDA regulatory strategy, transitioning from retrospective data to a hypothesis-driven, statistically-powered prospective clinical trial, increasing the number of subjects from 20 to about 250 to achieve statistical power.
ENDRA reduced operating expenses by over $3 million, approximately a 26% reduction on an annualized basis, without impacting key deliverables, such as clinical data collection for FDA submission.
The patent portfolio now includes 81 issued patents globally, with 5 additional patents issued in Q2 2024, covering thermoacoustic technology and other applications.
Positive feedback from an FDA meeting confirmed alignment on product configuration, clinical study design, and regulatory pathway, setting a clear path for the TAEUS liver device.
Good afternoon, and welcome to the ENDRA Life Sciences Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead.
Thank you, operator. This is Yvonne Briggs with LHA. Good afternoon and welcome to ENDRA Life Sciences’ Second Quarter 2024 Business Update and Financial Results Conference Call. Earlier today, ENDRA issued a press release on this topic, which is available in the Investors section of ENDRA’s website. Before we begin, please note that today's discussion will include forward-looking statements. All statements by management, other than statements of historical facts, including statements regarding the company's strategies, financial condition, operations, costs, plans, and objectives, as well as anticipated results of development and commercialization efforts, the timing of clinical studies, potential partnership opportunities, and expectations regarding regulatory processes, receipt of required regulatory clearances, and product launches are forward-looking statements. Except as required by federal securities laws, the company disclaims any obligation to update or revise any forward-looking statements. Please refer to the company's Form 10-K for the 2023 fiscal year and subsequent SEC filings for more information about risks and uncertainties related to forward-looking statements.
In terms of the structure of today's call, Alexander Tokman, Acting Chief Executive Officer, will b...